Showing results (71-80 of 109) with videos related to
Sort By:
Pageof 11
Kidney International|June 11, 2016
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsFrank B Cortazar, Kristen A Marrone, Megan L Troxell, et al.Journal of Translational Medicine|March 5, 2024
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockadeShuming Chen, Tracee L McMiller, Abha Soni, et al.Journal for Immunotherapy of Cancer|December 25, 2025
AstroID resource: a scalable, relational database structure for longitudinal biomarker discoveryElizabeth M Will, Benjamin F Green, Scott Carey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047Evan J Lipson, Sonia Dolfi, Hao Tang, et al.The Oncologist|July 27, 2024
Immune-related encephalitis after immune checkpoint inhibitor therapyMonica W Buckley, Aanika Balaji Warner, Julie Brahmer, et al.NEJM Evidence|February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced MelanomaGeorgina V Long, F Stephen Hodi, Evan J Lipson, et al.Journal of the National Cancer Institute|July 21, 2026
Summary recommendations from the NCI clinical trials planning meeting (CTPM) on advanced cutaneous squamous cell carcinoma in immunosuppressed patientsShlomo A Koyfman, Julie E Bauman, Mehrdad Mohseni, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse EventsJarushka Naidoo, Jiajia Zhang, Evan J Lipson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 TrialPaolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.Pageof 11